NovaBay Pharmaceuticals (NBY) and Eyenovia (EYEN) have commenced activities under a previously announced co-promotion agreement. Under the agreement, Eyenovia is leveraging its ten-person field salesforce to promote NovaBay’s Avenova Antimicrobial Lid & Lash Solution to large ophthalmic surgery centers along with one of Eyenovia’s other FDA-approved products, MydCombi for mydriasis. In parallel, NovaBay has initiated reconnaissance and market preparation activities ahead of Eyenovia’s launch of Clobetasol Propionate Ophthalmic Suspension, 0.05%, an innovative, rapid, sustained and more convenient solution for the treatment of postoperative inflammation and pain. Clobetasol is expected to be commercially available in August 2024. NovaBay will conduct outreach through its telephone-based physician dispensed channel to supplement geographic areas not covered by Eyenovia.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBY:
- NovaBay files to sell common stock and warrants, no amount given
- NovaBay files to sell 298,355 shares of common stock for holders
- NovaBay says NYSE American accepts plan to regain compliance
- NovaBay price target lowered to $1.60 from $3.20 at Ladenburg
- Facing the Fallout: The Consequences of Novabay Pharmaceuticals’ Potential Delisting from NYSE American